Henry Schein (NASDAQ:HSIC) Releases FY25 Earnings Guidance

Henry Schein (NASDAQ:HSIC) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $4.80-4.94 for the period, compared to the consensus estimate of $5.00. The company issued revenue guidance of ~$12.93-13.18 billion, compared to the consensus revenue estimate of $13.18 billion. Henry Schein also updated its FY 2025 guidance to 4.800-4.940 EPS.

Henry Schein Trading Down 2.7 %

Shares of Henry Schein stock traded down $2.04 during midday trading on Wednesday, reaching $73.78. The company had a trading volume of 1,386,994 shares, compared to its average volume of 1,613,700. The stock has a fifty day moving average price of $74.25 and a 200 day moving average price of $72.43. Henry Schein has a fifty-two week low of $63.67 and a fifty-two week high of $82.63. The firm has a market cap of $9.20 billion, a PE ratio of 30.36, a P/E/G ratio of 2.13 and a beta of 0.91. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, February 25th. The company reported $1.19 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.25 billion. During the same quarter last year, the firm posted $0.66 EPS. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. On average, equities analysts anticipate that Henry Schein will post 4.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HSIC has been the subject of several research analyst reports. Barrington Research reissued an “outperform” rating and issued a $90.00 price objective on shares of Henry Schein in a research report on Wednesday. Wells Fargo & Company assumed coverage on Henry Schein in a report on Friday, February 14th. They issued an “equal weight” rating and a $80.00 target price for the company. Jefferies Financial Group increased their price target on Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, January 23rd. Bank of America raised shares of Henry Schein from an “underperform” rating to a “buy” rating and raised their price objective for the stock from $69.00 to $84.00 in a research report on Monday, January 6th. Finally, Mizuho assumed coverage on shares of Henry Schein in a research report on Wednesday, December 4th. They set a “neutral” rating and a $75.00 target price on the stock. Eight analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Henry Schein has an average rating of “Moderate Buy” and a consensus target price of $80.09.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.